Shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) rose 19.7% during mid-day trading on Wednesday . The company traded as high as $0.86 and last traded at $0.79, approximately 381,844 shares traded hands during trading. An increase of 32% from the average daily volume of 289,209 shares. The stock had previously closed at $0.66.
SNNA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. cut shares of Sienna Biopharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, May 13th. ValuEngine upgraded shares of Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Sienna Biopharmaceuticals presently has a consensus rating of “Buy” and an average target price of $21.67.
The company has a debt-to-equity ratio of 1.11, a current ratio of 2.43 and a quick ratio of 2.43. The company’s 50 day moving average is $0.81 and its two-hundred day moving average is $1.67. The firm has a market cap of $20.40 million, a P/E ratio of -0.22 and a beta of 2.89.
Sienna Biopharmaceuticals Company Profile (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Read More: Neutral Rating
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.